(i) before the delivery of the Compliance Certificate relating to the Relevant Period immediately succeeding the expired Relevant Period during which the deficiency in relation to the relevant ratio was reported; and
When re-calculating the ratio of Book Equity to Total Assets pursuant to an Equity Cure, the Book Equity used in the calculations shall be increased with the Cure Amount on a SEK by SEK basis.
When re-calculating the ratio of Net Interest Bearing Debt to Property Value pursuant to an Equity Cure, the Net Interest Bearing Debt used in the calculations shall be decreased with the Cure Amount on a SEK by SEK basis.
When re-calculating the Interest Coverage Ratio pursuant to an Equity Cure, the Finance Charges shall be reduced by an amount corresponding to the amount with which the Finance Charges would have been reduced if the Cure Amount was applied towards a SEK by SEK reduction of the Financial Indebtedness relevant for the Finance Charges for the entire Relevant Period calculated pro forma and, when making the SEK by SEK reduction, based on the weighted average (blended rate) Finance Charges for such Financial Indebtedness for such period. For the avoidance of doubt, such pro forma calculation may be included when calculating the Finance Charges for subsequent Relevant Periods having overlapping interim periods with the Relevant Period which first included the pro forma calculation, however only taking into account such overlapping interim periods.
Only one Equity Cure is allowed during a twelve (12) month period and only two (2) Equity Cures may occur in aggregate prior to the Final Redemption Date.
Disposals of assets
The Issuer shall not, and shall procure that none of its Subsidiaries, sell or otherwise dispose of shares in any Group Company or of all or substantially all of its or any Group Company's assets or operations to any Person not being the Issuer or any of the wholly-owned Subsidiaries, unless the transaction (taken as a whole also taking into account any transaction ancillary or related thereto) is carried out at fair market value and on terms and conditions customary for such transaction and provided that it does not have a Material
20
Adverse Effect. The Issuer shall notify the Agent of any such transaction in accordance with Clause 12.10.2.
